Work

ANA Investigates: Debates in Idiopathic Normal Pressure Hydrocephalus and the PENS Trial

Year: 2026

Type: article

Abstract: A.L.G., I.Z., and J.H. have no conflicts of interest or disclosures. K.J.W. receives support from Bionie consulting (new, August 2025), which is ongoing; research support from UCB pharma, which ended June 2025, and Photopharmics, which is ongoing. M.A.W. is a paid consultant to Aesculap regarding devices to treat hydrocephalus, but which were not used in the PENS Trial. A.J.E. has received grant support from the NIH and The Michael J. Fox Foundation; personal compensation as a consultant/scientific advisory board member for Mitsubishi Tanabe Pharma America (formerly, Neuroderm), Amneal, Acorda, AbbVie, Bial, Supernus (formerly, USWorldMeds), NeuroDiagnostics (SYNAPS Dx), Intrance Medical Systems, Merz, Praxis Precision Medicines, Citrus Health, and Herantis Pharma; is on the Data Safety Monitoring Board (chair) of AskBio; and receives publishing royalties from Lippincott Williams and Wilkins, Cambridge University Press, and Springer. He is co-inventor of the patent “Compositions and methods for treatment and/or prophylaxis of proteinopathies” with which he cofounded REGAIN Therapeutics to fund preclinical studies. He has no financial relationship with the company and has relinquished the right to any personal income from future treatments. A.J.E. owns no stock in any pharmaceutical company with which he has a scientific advisory relationship. He serves on the editorial boards of the Journal of Parkinson's Disease, Journal of Alzheimer's Disease, European Journal of Neurology, Movement Disorders Clinical Practice, and JAMA Neurology.

Source: Annals of Neurology

DOI: 10.1002/ana.78258

Authors: Kara J. Wyant, Michael A. Williams, Alberto J. Espay, Jennifer Hurley, Adeline L. Goss, Ifrah Zawar